Nanocarriers as an emerging platform for cancer therapy

TL;DR: Cell uptake studies show that the GO-CMC-FI-HA/DOX complex can specifically target cancer cells, which are over-expressing CD44 receptors and effectively inhibit their growth.

TL;DR: Administration of this combinational drug delivery system can markedly augment the enrichment of drugs both in tumor tissues and cancer stem cells, prodigiously enhancing the suppression of tumor growth while reduce the incidence of CSC in a synergistic manner.

TL;DR: The results indicate that the rotation of nanoparticles, which is one of the most important mechanisms for endocytosis of shaped nanoparticle, regulates the competition between ligand-receptor binding and membrane deformation.

TL;DR: RPDSG/DOX nanoparticles display significantly higher anticancer efficacy than that of free DOX at concentrations higher than 5 μM and could be a promising nanotherapeutic for tumor-targeted chemotherapy.

TL;DR: The ability to predict and circumvent drug resistance is likely to improve chemotherapy, and it has become apparent that resistance exists against every effective drug, even the authors' newest agents.

TL;DR: For further successful development of this field, promising trends must be identified and exploited, albeit with a clear understanding of the limitations of these approaches.

TL;DR: Nanotechnology is a multidisciplinary field, which covers a vast and diverse array of devices derived from engineering, biology, physics and chemistry that can provide essential breakthroughs in the fight against cancer.

TL;DR: In vivo studies under magnetic resonance guidance revealed that exposure to low doses of NIR light in solid tumors treated with metal nanoshells reached average maximum temperatures capable of inducing irreversible tissue damage, and found good correlation with histological findings.